Strasbourg Cedex

• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat … Recruiting
  2022-502851-79-00 5 2023-09-20 Active Idiopathic Inflammatory Myopathy (IIM)
• Best Antithrombotic Therapy in patients with acute Venous ThromboEmbolism while taking antiplatelets: the BAT-VTE Recruiting
  2022-500974-33-00 5 2023-08-12 acute venous thromboembolism event
• Aspirin for the Prevention of Preeclampsia and Pregnancy outcomes in nulliparous women after Assisted Reproductive Technology. Recruiting
  2022-500933-10-00 11 2023-08-02 Preeclampsia during pregnancy
• Effect of early use of levosimendan versus placebo on top of a conventional strategy of inotrope use on a combined morbidity-mortality endpo … Recruiting
  2024-513811-29-00 5 2023-07-03 Cardiogenic Shock
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1) Recruiting
  2022-500699-76-00 5 2023-05-18 Active Systemic Lupus Erythematosus (SLE)
• PROPHYLOXITIN-Intermittent cefoxitin administration versus loading bolus followed by continuous infusion for the prevention of surgical site … Recruiting
  2024-515146-16-00 5 2023-05-15 Colorectal surgery
• A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors (VAPOR (GETUG T06)) Recruiting
  2023-505040-19-00 4 2023-04-11 Non-seminomatous germ-cell tumors (including testis, retroperitoneal a
• NAlmefene versus placebo in addition to treatment as usual on craving in Behavioural Addictions (NABAb) Recruiting
  2022-500085-96-00 5 2023-03-31 Patients with gambling disorder or sexual addiction or food addiction
• REVERT : REVErsing airway Remodelling with Tezepelumab Recruiting
  2024-513195-18-00 5 2023-03-27 Severe asthma
• Study of efficacy and safety of LNP023 in participants with active lupus nephritis Class III-IV, +/- V Recruiting
  2023-509332-26-00 4 2023-02-16 Lupus Nephritis Class III-IV, +/- V
• EvER-ILD 2: Evaluation of Efficacy and safety of Rituximab in patients with progressive Interstitial Lung Disease (ILD) with inflammatory co … Recruiting
  2022-501335-16-00 10 2023-01-16 Interstitial lung disease
• Efficacy of a sequential treatment strategy in Rheumatoid Arthritis. Recruiting
  2022-500234-29-00 5 2022-11-28 Rheumatoid Arthritis
• Intravenous Immunoglobulins for Prevention of BKV Viremia in Kidney Transplant Recipients According to BKV genotype-specific Neutralizing An … Recruiting
  2024-515243-37-00 11 2022-08-21 Kidney Transplantation BKV infection
• An outpatient study to learn if Staccato Alprazolam is safe and effective when treating long seizures in children ≥12 years of age and adult … Recruiting
  2024-510950-29-00 5 2022-07-21 Stereotypical prolonged seizure
• A study to evaluate efficacy and safety of an investigational drug named volixibat in patients with itching caused by primary biliary cholan … Recruiting
  2023-504660-41-00 4 2022-07-11 Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (PBC
• A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) afte … Recruiting
  2024-515945-40-00 10 2022-05-02 Non small cell lung cancer
• PEMBROCABOSARC : Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas Recruiting
  2023-509496-16-00 4 2022-04-21 Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, o
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• STUDY TO ASSESS THE SCHEMAS OF RETREATMENT WITH LUTATHERA® IN PATIENTS WITH NEW PROGRESSION OF INTESTINAL WELL-DIFFERENTIATED NEUROENDOCRINE … Recruiting
  2024-511001-28-00 4 2021-12-13 Neuroendocrine tumor
• Multicenter randomized two arms study evaluating the efficacy of prophylactic Rituximab in EBV negative kidney transplant recipients on inci … Recruiting
  2024-515075-36-00 6 2021-12-01 kidney transplantion -Epstein Barr virus
• Predictive Signature of Benralizumab Response. BENRAPRED Study. Recruiting
  2024-514843-27-00 6 2021-10-11 Severe asthma
• Short Treatment With Omalizumab for Severe Asthma (SHORTEN) Recruiting
  2024-513427-17-00 6 2021-05-20 Well controlled severe allergic asthma
• Phase 2, Open label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in patients with advanced and/or unresectable Non-Small … Recruiting
  2023-505924-71-00 4 2021-05-12 Adult patients with metastatic and/or unresectable Non-Small Cell Lung
• Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma … Recruiting
  2023-508922-83-00 10 2021-03-17 Advanced Non-Small Cell Lung Cancer

Showing 121–144 of 291 trials